{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:51:44Z","timestamp":1790009504617,"version":"4.0.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:00:00Z","timestamp":1537315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:00:00Z","timestamp":1537315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s40263-018-0569-6","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T09:15:13Z","timestamp":1537348513000},"page":"997-1009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Ketamine for Refractory Status Epilepticus: A Systematic Review"],"prefix":"10.1007","volume":"32","author":[{"given":"Anna","family":"Rosati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"De Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Guerrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,19]]},"reference":[{"key":"569_CR1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","volume":"22","author":"Commission on Classification and Terminology of the International","year":"1981","unstructured":"Commission on Classification and Terminology of the International. League Against Epilepsy. Proposal for revised clinical and electrographic classification of epileptic seizures. Epilepsia. 1981;22:489\u2013501.","journal-title":"Epilepsia"},{"key":"569_CR2","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","volume":"56","author":"E Trinka","year":"2015","unstructured":"Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus: report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56:1515\u201323.","journal-title":"Epilepsia"},{"key":"569_CR3","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1093\/brain\/awr215","volume":"134","author":"S Shorvon","year":"2011","unstructured":"Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134:2802\u201318.","journal-title":"Brain"},{"key":"569_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","volume":"17","author":"GM Brophy","year":"2012","unstructured":"Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3\u201323.","journal-title":"Neurocrit Care"},{"key":"569_CR5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.pediatrneurol.2008.01.001","volume":"38","author":"NS Abend","year":"2008","unstructured":"Abend NS, Duglas DT. Treatment of refractory status epilepticus: literature review and a proposed protocol. Pediatr Neurol. 2008;38:377\u201380.","journal-title":"Pediatr Neurol"},{"key":"569_CR6","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1177\/0883073809332768","volume":"24","author":"K Sofou","year":"2009","unstructured":"Sofou K, Kristjansd\u00f2ttir R, Papachatzakis N, Ahmadzadeh A, Uvebrant P. Management of prolonged seizures and status epilepticus in childhood: a systematic review. J Child Neurol. 2009;24:918\u201326.","journal-title":"J Child Neurol"},{"key":"569_CR7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/MCC.0b013e32835132cc","volume":"18","author":"A Fernandez","year":"2012","unstructured":"Fernandez A, Claassen J. Refractory status epilepticus. Curr Opin Crit Care. 2012;18:127\u201331.","journal-title":"Curr Opin Crit Care"},{"key":"569_CR8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.yebeh.2015.05.007","volume":"49","author":"M Leitinger","year":"2015","unstructured":"Leitinger M, Beniczky S, Rohracher A, et al. Salzburg consensus criteria for non-convulsive status epilepticus: approach to clinical application. Epilepsy Behav. 2015;49:158\u201363.","journal-title":"Epilepsy Behav"},{"key":"569_CR9","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(07)70074-1","volume":"6","author":"H Meierkord","year":"2007","unstructured":"Meierkord H, Holtkamp M. Non-convulsive status epilepticus in adults: clinical forms and treatment. Lancet Neurol. 2007;6:329\u201339.","journal-title":"Lancet Neurol"},{"issue":"Suppl. 9","key":"569_CR10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1528-1167.2008.01928.x","volume":"49","author":"CG Wasterlain","year":"2008","unstructured":"Wasterlain CG, Chen JW. Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs. Epilepsia. 2008;49(Suppl. 9):63\u201373.","journal-title":"Epilepsia"},{"issue":"Suppl. 3","key":"569_CR11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1528-1167.2010.02622.x","volume":"5","author":"DE Naylor","year":"2010","unstructured":"Naylor DE. Glutamate and GABA in the balance: convergent pathways sustain seizures during status epilepticus. Epilepsia. 2010;5(Suppl. 3):106\u20139.","journal-title":"Epilepsia"},{"key":"569_CR12","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s12028-013-9939-6","volume":"20","author":"FA Zeiler","year":"2014","unstructured":"Zeiler FA, Teitelbaum J, Gillman LM, West M. NMDA antagonists for refractory seizures. Neurocrit Care. 2014;20:502\u201313.","journal-title":"Neurocrit Care"},{"key":"569_CR13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/cns.12096","volume":"19","author":"F Dorandeu","year":"2013","unstructured":"Dorandeu F, Dhote F, Barbier L, Baccus B, Testylier G. Treatment of status epilepticus with ketamine, are we there yet? CNS Neurosci Ther. 2013;19:411\u201327.","journal-title":"CNS Neurosci Ther"},{"key":"569_CR14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0920-1211(00)00175-3","volume":"42","author":"DJ Borris","year":"2000","unstructured":"Borris DJ, Bertram EH, Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res. 2000;42:117\u201322.","journal-title":"Epilepsy Res"},{"key":"569_CR15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1528-1167.2007.01384.x","volume":"49","author":"BS Martin","year":"2008","unstructured":"Martin BS, Kapur J. A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation. Epilepsia. 2008;49:248\u201355.","journal-title":"Epilepsia"},{"key":"569_CR16","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/epi.13480","volume":"57","author":"J Niquet","year":"2016","unstructured":"Niquet J, Baldwin R, Norman K, Suchomelova L, Lumley L, Wasterlain CG. Midazolam-ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits. Epilepsia. 2016;57:1406\u201315.","journal-title":"Epilepsia"},{"key":"569_CR17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70:621\u201360.","journal-title":"Pharmacol Rev"},{"key":"569_CR18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2044.2007.05298.x","volume":"62","author":"R Craven","year":"2007","unstructured":"Craven R. Ketamine. Anaesthesia. 2007;62:48\u201353.","journal-title":"Anaesthesia"},{"key":"569_CR19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/bja\/ael192","volume":"97","author":"S Shibuta","year":"2006","unstructured":"Shibuta S, Varathan S, Mashimo T. Ketamine and thiopental sodium: individual and combined neuroprotective effects on cortical cultures exposed to NMDA or nitric oxide. Br J Anaesth. 2006;97:517\u201324.","journal-title":"Br J Anaesth"},{"issue":"Suppl. 8","key":"569_CR20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1528-1167.2011.03233.x","volume":"52","author":"E Schmutzhard","year":"2011","unstructured":"Schmutzhard E, Pfausler B. Complications of the management of status epilepticus in the intensive care unit. Epilepsia. 2011;52(Suppl. 8):39\u201341.","journal-title":"Epilepsia"},{"key":"569_CR21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cbi.2012.09.013","volume":"203","author":"F Dorandeu","year":"2013","unstructured":"Dorandeu F, Barbier L, Dhote F, Testylier G, Carpentier P. Ketamine combinations for the field treatment of soman-induced self-sustaining status epilepticus: review of current data and perspectives. Chem Biol Interact. 2013;203:154\u20139.","journal-title":"Chem Biol Interact"},{"key":"569_CR22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.yebeh.2015.06.019","volume":"49","author":"L Ilvento","year":"2015","unstructured":"Ilvento L, Rosati A, Marini C, L\u2019Erario M, Mirabile L, Guerrini R. Ketamine in refractory convulsive status epilepticus in children avoids endotracheal intubation. Epilepsy Behav. 2015;49:343\u20136.","journal-title":"Epilepsy Behav"},{"key":"569_CR23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1017\/cjn.2015.16","volume":"42","author":"FA Zeiler","year":"2015","unstructured":"Zeiler FA, West M. Ketamine for status epilepticus: Canadian physician views and time to push forward. Can J Neurol Sci. 2015;42:132\u20134.","journal-title":"Can J Neurol Sci"},{"key":"569_CR24","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"569_CR25","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136.","journal-title":"BMJ"},{"key":"569_CR26","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Sch\u00fcnemann HJ, et al. Rating quality of evidence and strength of recommendations: what is \u201cquality of evidence\u201d and why is it important to clinicians? BMJ. 2008;336:995\u20138.","journal-title":"BMJ"},{"issue":"Suppl. 3","key":"569_CR27","first-page":"17","volume":"54","author":"A Rosati","year":"2013","unstructured":"Rosati A, L\u2019Erario M, Ilvento L, Pisano T, Mirable L, Guerrini R. An ongoing open-label uncontrolled study of the efficacy and safety of ketamine in children with refractory status epilepticus. Epilepsia. 2013;54(Suppl. 3):17.","journal-title":"Epilepsia"},{"key":"569_CR28","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1212\/WNL.0b013e318278b685","volume":"79","author":"A Rosati","year":"2012","unstructured":"Rosati A, L\u2019Erario M, Ilvento L, Cecchi C, Pisano T, Mirabile L, et al. Efficacy and safety of ketamine in refractory status epilepticus in children. Neurology. 2012;79:2355\u20138.","journal-title":"Neurology"},{"issue":"Suppl. 7","key":"569_CR29","first-page":"282","volume":"43","author":"TP Bleck","year":"2002","unstructured":"Bleck TP, Quigg MS, Nathan BR, Smith TL, Kapur J. Electroencephalographic effects of ketamine treatment for refractory status epilepticus. Epilepsia. 2002;43(Suppl. 7):282.","journal-title":"Epilepsia"},{"issue":"Suppl. 11","key":"569_CR30","first-page":"63","volume":"50","author":"D Singh","year":"2009","unstructured":"Singh D, Kelly K, Rana S, Valeriano J. Use of ketamine in treating refractory status epilepticus. Epilepsia. 2009;50(Suppl. 11):63.","journal-title":"Epilepsia"},{"key":"569_CR31","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/epi.12247","volume":"54","author":"N Gaspard","year":"2013","unstructured":"Gaspard N, Foreman B, Judd LM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54:1498\u2013503.","journal-title":"Epilepsia"},{"issue":"Suppl. 1","key":"569_CR32","first-page":"S31","volume":"40","author":"S Gosselin-Lefebvre","year":"2013","unstructured":"Gosselin-Lefebvre S, Rabinstein A, Rossetti A, Savard M. Ketamine usefulness in refractory status epilepticus: a retrospective multicenter study. Can J Neurol Sci. 2013;40(Suppl. 1):S31.","journal-title":"Can J Neurol Sci"},{"key":"569_CR33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.eplepsyres.2013.01.007","volume":"105","author":"AS Synowiec","year":"2013","unstructured":"Synowiec AS, Singh DS, Yenugadhati V, et al. Ketamine use in the treatment of refractory status epilepticus. Epilepsy Res. 2013;105:183\u20138.","journal-title":"Epilepsy Res"},{"key":"569_CR34","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1111\/epi.12947","volume":"56","author":"MM Basha","year":"2015","unstructured":"Basha MM, Alqallaf A, Shah AK. Drug-induced EEG pattern predicts effectiveness of ketamine in treating refractory status epilepticus. Epilepsia. 2015;56:e44\u20138.","journal-title":"Epilepsia"},{"key":"569_CR35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.yebeh.2015.07.040","volume":"52","author":"V Sabharwal","year":"2015","unstructured":"Sabharwal V, Ramsay E, Martinez R, Shumate R, Khan F, Dave H, Iwuchukwu I, McGrade H. Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus. Epilepsy Behav. 2015;52:264\u20136.","journal-title":"Epilepsy Behav"},{"key":"569_CR36","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40263-016-0371-2","volume":"30","author":"J H\u00f6fler","year":"2016","unstructured":"H\u00f6fler J, Rohracher A, Kalss G, Zimmermann G, Dobesberger J, Pilz G, Leitinger M, Kuchukhidze G, Butz K, Taylor A, Novak H, Trinka E. (S)-Ketamine in refractory and super-refractory status epilepticus: a retrospective study. CNS Drugs. 2016;30:869\u201376.","journal-title":"CNS Drugs"},{"key":"569_CR37","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/qjmed\/89.12.913","volume":"89","author":"MC Walker","year":"1996","unstructured":"Walker MC, Howard RS, Smith SJ, et al. Diagnosis and treatment of status epilepticus on a neurological intensive care unit. QJM. 1996;89:913\u201320.","journal-title":"QJM"},{"key":"569_CR38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S1525-5050(02)00643-1","volume":"4","author":"EE Ubogu","year":"2003","unstructured":"Ubogu EE, Sagar SM, Lerner AJ, et al. Ketamine for refractory status epilepticus: a case of possible ketamine induced neurotoxicity. Epilepsy Behav. 2003;4:70\u20135.","journal-title":"Epilepsy Behav"},{"key":"569_CR39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1385\/NCC:4:1:035","volume":"4","author":"TK Robakis","year":"2006","unstructured":"Robakis TK, Hirsch LJ. Literature review, case report, and expert discussion of prolonged refractory status epilepticus. Neurocrit Care. 2006;4:35\u201346.","journal-title":"Neurocrit Care"},{"key":"569_CR40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.eplepsyres.2008.08.005","volume":"82","author":"H Pr\u00fcss","year":"2008","unstructured":"Pr\u00fcss H, Holtkamp M. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res. 2008;82:219\u201322.","journal-title":"Epilepsy Res"},{"key":"569_CR41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/WNF.0b013e3181d1e3cd","volume":"33","author":"CY Hsieh","year":"2010","unstructured":"Hsieh CY, Sung PS, Tsai JJ, et al. Terminating prolonged refractory status epilepticus using ketamine. Clin Neuropharmacol. 2010;33:165\u20137.","journal-title":"Clin Neuropharmacol"},{"key":"569_CR42","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.seizure.2011.06.001","volume":"20","author":"PS Yeh","year":"2011","unstructured":"Yeh PS, Shen HN, Chen TY. Oral ketamine controlled refractory nonconvulsive status epilepticus in an elderly patient. Seizure. 2011;20:723\u20136.","journal-title":"Seizure"},{"key":"569_CR43","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12028-011-9668-7","volume":"16","author":"AH Kramer","year":"2012","unstructured":"Kramer AH. Early ketamine to treat refractory status epilepticus. Neurocrit Care. 2012;16:299\u2013305.","journal-title":"Neurocrit Care"},{"key":"569_CR44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12028-013-9858-6","volume":"19","author":"FA Zeiler","year":"2013","unstructured":"Zeiler FA, Kaufmann AM, Gillman LM, et al. Ketamine for medically refractory status epilepticus after elective aneurysm clipping. Neurocrit Care. 2013;19:119\u201324.","journal-title":"Neurocrit Care"},{"key":"569_CR45","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1177\/1060028013505427","volume":"47","author":"D Esaian","year":"2013","unstructured":"Esaian D, Joset D, Lazarovits C, Dugan PC, Fridman D. Ketamine continuous infusion for refractory status epilepticus in a patient with anticonvulsant hypersensitivity syndrome. Ann Pharmacother. 2013;47:1569\u201376.","journal-title":"Ann Pharmacother"},{"key":"569_CR46","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4103\/0972-5229.156484","volume":"19","author":"GS Shrestha","year":"2015","unstructured":"Shrestha GS, Joshi P, Chhetri S, et al. Intravenous ketamine for treatment of super-refractory convulsive status epilepticus with septic shock: a report of two cases. Indian J Crit Care Med. 2015;19:283\u20135.","journal-title":"Indian J Crit Care Med"},{"key":"569_CR47","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/WNF.0000000000000128","volume":"39","author":"KA McGinn","year":"2016","unstructured":"McGinn KA, Bishop L, Sarwal A. Use of ketamine in barbiturate coma for status epilepticus. Clin Neuropharmacol. 2016;39:62\u20135.","journal-title":"Clin Neuropharmacol"},{"key":"569_CR48","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000447295","volume":"8","author":"P Dillien","year":"2016","unstructured":"Dillien P, Ferrao Santos S, van Pesch V, Suin V, Lamoral S, Hantson P. New-onset refractory status epilepticus: more investigations, more questions. Case Rep Neurol. 2016;8:127\u201333.","journal-title":"Case Rep Neurol"},{"key":"569_CR49","doi-asserted-by":"crossref","first-page":"247","DOI":"10.5001\/omj.2017.46","volume":"32","author":"M Al-Busaidi","year":"2017","unstructured":"Al-Busaidi M, Burad J, Al-Belushi A, Gujjar A. Super refractory status epilepticus in Hashimoto\u2019s encephalopathy. Oman Med J. 2017;32:247\u201350.","journal-title":"Oman Med J"},{"key":"569_CR50","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40560-017-0248-6","volume":"5","author":"MA Pizzi","year":"2017","unstructured":"Pizzi MA, Kamireddi P, Tatum WO, Shih JJ, Jackson DA, Freeman WD. Transition from intravenous to enteral ketamine for treatment of nonconvulsive status epilepticus. J Intensive Care. 2017;5:54.","journal-title":"J Intensive Care"},{"key":"569_CR51","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jocn.2017.10.044","volume":"47","author":"L Koffman","year":"2018","unstructured":"Koffman L, Yan Yiu H, Farrokh S, Lewin J, Geocadin R, Ziai W. Ketamine infusion for refractory status epilepticus: a case report of cardiac arrest. J Clin Neurosci. 2018;47:149\u201351.","journal-title":"J Clin Neurosci"},{"key":"569_CR52","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/ijccm.IJCCM_370_17","volume":"22","author":"DP Mutkule","year":"2018","unstructured":"Mutkule DP, Rao SM, Chaudhuri JR, Rajasri K. Successful use of ketamine for burst suppression in super refractory status epilepticus following substance Abuse. Indian J Crit Care Med. 2018;22:49\u201350.","journal-title":"Indian J Crit Care Med"},{"key":"569_CR53","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1059-1311(03)00028-1","volume":"12","author":"LD Mewasingh","year":"2003","unstructured":"Mewasingh LD, Sekhara T, Aeby A, Christiaens FJC, Dan B. Oral ketamine in paediatric non-convulsive status epilepticus. Seizure. 2003;12:483\u20139.","journal-title":"Seizure"},{"issue":"Suppl. 462","key":"569_CR54","first-page":"107","volume":"99","author":"R Kravljanac","year":"2010","unstructured":"Kravljanac R, Nikolic LJ, Djuric M, Jovic N, Jankovic B. Treatment of status epilepticus in children: 15-year single center experience. Acta Paediatr. 2010;99(Suppl. 462):107.","journal-title":"Acta Paediatr"},{"issue":"3 Suppl. 1","key":"569_CR55","first-page":"S69","volume":"37","author":"AD Al-Otaibi","year":"2010","unstructured":"Al-Otaibi AD, McCoy B, Cortez M, Hutchison JS, Hahn CS. The use of ketamine in refractory status epilepticus. Can J Neurol Sci. 2010;37(3 Suppl. 1):S69.","journal-title":"Can J Neurol Sci"},{"key":"569_CR56","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1212\/WNL.51.6.1765","volume":"51","author":"RD Sheth","year":"1998","unstructured":"Sheth RD, Gidal BE. Refractory status epilepticus: response to ketamine. Neurology. 1998;51:1765\u20136.","journal-title":"Neurology"},{"key":"569_CR57","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/08830738050200030301","volume":"20","author":"U Kramer","year":"2005","unstructured":"Kramer U, Shorer Z, Ben-Zeev B, Lerman-Sagie T, Goldberg-Stern H, Lahat E. Severe refractory status epilepticus owing to presumed encephalitis. J Child Neurol. 2005;20:184\u20137.","journal-title":"J Child Neurol"},{"key":"569_CR58","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ejpn.2009.12.001","volume":"14","author":"JW Elting","year":"2010","unstructured":"Elting JW, Naalt JV, Fock JM. Mild hypothermia for refractory focal status epilepticus in an infant with hemimegalencephaly. Eur J Paediatr Neurol. 2010;14:452\u20135.","journal-title":"Eur J Paediatr Neurol"},{"key":"569_CR59","first-page":"98","volume":"53","author":"C Andrade","year":"2012","unstructured":"Andrade C, Franca S, Sampaio M, et al. Successful use of ketamine in paediatric super-refractory status epilepticus\u2014case report. Epilepsia. 2012;53:98.","journal-title":"Epilepsia"},{"key":"569_CR60","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.pediatrneurol.2014.03.006","volume":"51","author":"A Tarocco","year":"2014","unstructured":"Tarocco A, Ballardini E, Garani G. Use of ketamine in a newborn with refractory status epilepticus: a case report. Pediatr Neurol. 2014;51:154\u20136.","journal-title":"Pediatr Neurol"},{"key":"569_CR61","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.braindev.2016.03.010","volume":"38","author":"A Horino","year":"2016","unstructured":"Horino A, Kawawaki H, Fukuoka M, et al. A case of succinic semialdehyde dehydrogenase deficiency with status epilepticus and rapid regression. Brain Dev. 2016;38:866\u201370.","journal-title":"Brain Dev"},{"key":"569_CR62","first-page":"45","volume":"48","author":"A Mir\u00e1s Veiga","year":"2017","unstructured":"Mir\u00e1s Veiga A, Moreno DC, Men\u00e9ndez AI, et al. Effectiveness of electroconvulsive therapy for refractory status epilepticus in febrile infection-related epilepsy syndrome. Neuropaediatrics. 2017;48:45\u20138.","journal-title":"Neuropaediatrics"},{"key":"569_CR63","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ejpn.2016.08.004","volume":"20","author":"F Chiusolo","year":"2016","unstructured":"Chiusolo F, Diamanti A, Bianchi R, et al. From intravenous to enteral ketogenic diet in PICU: a potential treatment strategy for refractory status epilepticus. Eur J Paediatr Neurol. 2016;20:843\u20137.","journal-title":"Eur J Paediatr Neurol"},{"key":"569_CR64","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ajhg.2016.07.013","volume":"99","author":"D Li","year":"2016","unstructured":"Li D, Yuan H, Ortiz-Gonzalez XR, et al. GRIN2D recurrent de novo dominant mutation causes a severe epileptic encephalopathy treatable with NMDA receptor channel blockers. Am J Hum Genet. 2016;99:802\u201316.","journal-title":"Am J Hum Genet"},{"key":"569_CR65","first-page":"SR01","volume":"11","author":"S Aroor","year":"2017","unstructured":"Aroor S, Shravan K, Mundkur SC, Jayakrishnan C, Rao SS. Super-refractory status epilepticus: a therapeutic challenge in paediatrics. J Clin Diagn Res. 2017;11:SR01\u20134.","journal-title":"J Clin Diagn Res"},{"key":"569_CR66","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejpn.2017.11.005","volume":"22","author":"D Caputo","year":"2018","unstructured":"Caputo D, Iorio R, Vigevano F, Fusco L. Febrile infection-related epilepsy syndrome (FIRES) with super-refractory status epilepticus revealing autoimmune encephalitis due to GABAAR antibodies. Eur J Paediatr Neurol. 2018;22:182\u20135.","journal-title":"Eur J Paediatr Neurol"},{"key":"569_CR67","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yebeh.2015.02.027","volume":"49","author":"W L\u00f6scher","year":"2015","unstructured":"L\u00f6scher W. Single versus combinatorial therapies in status epilepticus: novel data from preclinical models. Epilepsy Behav. 2015;49:20\u20135.","journal-title":"Epilepsy Behav"},{"key":"569_CR68","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s00134-008-1205-6","volume":"34","author":"DE Griesdale","year":"2008","unstructured":"Griesdale DE, Bosma TL, Kurth T, Isac G, Chittock DR. Complications of endotracheal intubation in the critically ill. Int Care Med. 2008;34:1835\u201342.","journal-title":"Int Care Med"},{"key":"569_CR69","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PCC.0b013e3181ce6d19","volume":"11","author":"CL Carroll","year":"2010","unstructured":"Carroll CL, Spinella PC, Corsi JM, Stoltz P, Zucker AR. Emergent endotracheal intubations in children: be careful if it\u2019s late when you intubate. Pediatr Crit Care Med. 2010;11:343\u20138.","journal-title":"Pediatr Crit Care Med"},{"key":"569_CR70","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1528-1157.1995.tb00979.x","volume":"36","author":"DG Fujikawa","year":"1995","unstructured":"Fujikawa DG. Neuroprotective effect of ketamine administered after status epilepticus onset. Epilepsia. 1995;36:186\u201395.","journal-title":"Epilepsia"},{"key":"569_CR71","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1742-7843.2009.00403.x","volume":"104","author":"AO Cunha","year":"2009","unstructured":"Cunha AO, Mortari MR, Liberato JL, dos Santos WF. Neuroprotective effects of diazepam, carbamazepine, phenytoin and ketamine after pilocarpine-induced status epilepticus. Basic Clin Pharmacol Toxicol. 2009;104:470\u20137.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"569_CR72","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.tox.2007.02.012","volume":"234","author":"F Dorandeu","year":"2007","unstructured":"Dorandeu F, Baille V, Mikler J, et al. Protective effects of S+ ketamine and atropine against lethality and brain damage during soman-induced status epilepticus in guinea-pigs. Toxicology. 2007;234:185\u201393.","journal-title":"Toxicology"},{"issue":"42","key":"569_CR73","doi-asserted-by":"crossref","first-page":"26954","DOI":"10.18632\/oncotarget.25485","volume":"9","author":"K Vargas-S\u00e1nchez","year":"2018","unstructured":"Vargas-S\u00e1nchez K, Mogilevskaya M, Rodr\u00edguez-P\u00e9rez J, Rubiano MG, Javela JJ, Gonz\u00e1lez-Reyes RE. Astroglial role in the pathophysiology of status epilepticus: an overview. Oncotarget. 2018;9(42):26954\u201376.","journal-title":"Oncotarget"},{"key":"569_CR74","first-page":"47","volume":"62","author":"S Loix","year":"2011","unstructured":"Loix S, De Kock M, Henin P. The anti-inflammatory effects of ketamine: state of the art. Acta Anaesthesiol Belg. 2011;62:47\u201358.","journal-title":"Acta Anaesthesiol Belg"},{"key":"569_CR75","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/14737175.2017.1288099","volume":"17","author":"F Dorandeu","year":"2017","unstructured":"Dorandeu F. Ketamine for the treatment of (super) refractory status epilepticus? Not quite yet. Expert Rev Neurother. 2017;17:419\u201321.","journal-title":"Expert Rev Neurother"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0569-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0569-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T14:41:56Z","timestamp":1604068916000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0569-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,19]]},"references-count":75,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0569-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,19]]},"assertion":[{"value":"19 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were received for the preparation of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Anna Rosati, Salvatore De Masi and Renzo Guerrini have no conflicts of interest that are directly relevant to the contents of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}